Fatty Liver Disease - Should My Patients Worry?

Presenter(s)

• 

  Harold Bays, MD

  Medical Director/President
  Louisville Metabolic and Atherosclerosis Research Center, Inc.
  Louisville, Kentucky

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) represent a major health burden in industrialized countries. This session will discuss standard therapies that broadly impact the gut microbiome with use of antibiotics, probiotics, or fecal transplants, and how these therapies may be replaced by more targeted therapies that directly impact the pathophysiology of liver disease.

Learning Objectives:

• Identify non-alcoholic fatty liver disease (NAFLD) as the most common cause of common liver disease
• Contrast hepatosteatosis versus hepatosteatitis
• Diagnose and treat NAFLD